BridgeBio Pharma
BBIO
75 hedge funds and large institutions have $2.22B invested in BridgeBio Pharma in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 18 closing their positions.
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
23% more funds holding
Funds holding: 61 → 75 (+14)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
1.58% more ownership
Funds ownership: 86.89% → 88.47% (+1.6%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
18% less capital invested
Capital invested by funds: $2.7B → $2.22B (-$478M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$56.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.7M |
| 3 |
BlackRock
New York
|
+$39.3M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$10.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.5M |
| 2 |
Millennium Management
New York
|
-$9.48M |
| 3 |
JP Morgan Chase
New York
|
-$9.09M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$7.81M |
| 5 |
SM
SCGE Management
Menlo Park,
California
|
-$4.77M |
BBIO Hedge Fund Activity: Q3 2019 in Review
75 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2019, worth a combined $2.22B — down 18% from $2.7B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BBIO positions and 18 closed out — a net gain of 15 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was HHLR Advisors, adding an estimated $56.3M. The largest seller was Fidelity Investments, cutting an estimated $10.5M.
- 75 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2019, up from 61 in Q2 2019.
- Funds reported $2.22B of BridgeBio Pharma stock for Q3 2019, down 18% quarter-over-quarter.
- 33 funds opened new BridgeBio Pharma positions in Q3 2019 and 18 closed out, a net change of +15 holders.
- The largest BridgeBio Pharma buyer in Q3 2019 was HHLR Advisors, an estimated $56.3M added.
- The largest BridgeBio Pharma seller in Q3 2019 was Fidelity Investments, an estimated $10.5M sold.
Based on aggregated 13F filings for Q3 2019.